Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H22O8 |
Molecular Weight | 414.4053 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(=CC(OC)=C1OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](O)C4=CC5=C(OCO5)C=C24
InChI
InChIKey=YJGVMLPVUAXIQN-XVVDYKMHSA-N
InChI=1S/C22H22O8/c1-25-16-4-10(5-17(26-2)21(16)27-3)18-11-6-14-15(30-9-29-14)7-12(11)20(23)13-8-28-22(24)19(13)18/h4-7,13,18-20,23H,8-9H2,1-3H3/t13-,18+,19-,20-/m0/s1
DescriptionSources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=affc1058-7355-4486-8b65-378fea6f9454Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/?term=9562603
http://products.sanofi.ca/en/condyline.pdf
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=affc1058-7355-4486-8b65-378fea6f9454
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/?term=9562603
http://products.sanofi.ca/en/condyline.pdf
Podofilox ((abbreviated as PPT), otherwise known as podofilox) is an antimitotic drug which can be chemically synthesized or purified from the plant families Coniferae and Berberidaceae (e.g. species of Juniperus and Podophyllum). Podofilox 0.5% solution is indicated for the topical treatment of external genital warts (Condyloma acuminatum). This product is not indicated in the treatment of perianal or mucous membrane warts. Treatment of genital warts with podofilox results in necrosis of visible wart tissue. The exact mechanism of action is unknown, but is believed to exert its antimitotic effect by binding to tubulin, at a site close to but not identical to the binding site of colchicine; it is thought that this antimitotic effect causes necrosis of wart tissue, the observed clinical effect. In addition, podofilox is known to interfere with nucleoside transport, which may also contribute to its action. Adverse effects reported in less than 5% of the patients included pain with intercourse, insomnia, tingling, bleeding, tenderness, chafing, malodor, dizziness, scarring, vesicle formation, crusting edema, dryness/peeling, foreskin irretraction, hematuria, vomiting and ulceration.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095182 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2011590 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CONDYLOX Approved UsePodofilox Topical Solution 0.5% is indicated for the topical treatment of external genital warts (Condyloma acuminatum). This product is not indicated in the treatment of perianal or mucous membrane warts (see PRECAUTIONS ). Diagnosis Although genital warts have a characteristic appearance, histopathologic confirmation should be obtained if there is any doubt of the diagnosis. Differentiating warts from squamous cell carcinoma (so-called Bowenoid papulosis) is of particular concern. Squamous cell carcinoma may also be associated with human papillomavirus but should not be treated with Podofilox Topical Solution 0.5%. Launch Date1990 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
17 ng/mL |
1.5 mL single, topical dose: 1.5 mL route of administration: Topical experiment type: SINGLE co-administered: |
PODOFILOX plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.5 h |
1.5 mL single, topical dose: 1.5 mL route of administration: Topical experiment type: SINGLE co-administered: |
PODOFILOX plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult |
Other AEs: Inflammation, Pain... Other AEs: Inflammation (49.4%) Sources: Pain (54.3%) Itching (59.3%) Bleeding (29.6%) |
0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult |
Other AEs: Inflammation, Pain... Other AEs: Inflammation (79.2%) Sources: Pain (79.2%) Itching (83.3%) Bleeding (45.8%) |
0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult |
Other AEs: Inflammation, Pain... Other AEs: Inflammation (52.3%) Sources: Pain (55.8%) Itching (60.5%) Bleeding (32.6%) |
0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult |
Other AEs: Inflammation, Pain... Other AEs: Inflammation (83.2%) Sources: Pain (49.6%) Itching (52.9%) Bleeding (28.6%) |
0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult |
Other AEs: Inflammation, Pain... Other AEs: Inflammation (71.4%) Sources: Pain (71.4%) Itching (57.1%) |
0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult |
Other AEs: Inflammation, Pain... Other AEs: Inflammation (81.9%) Sources: Pain (50.4%) Itching (52.8%) Bleeding (26.8%) |
0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Other AEs: Inflammation, Pain... Other AEs: Inflammation (mild, 32.2%) Sources: Pain (mild, 23.7%) Itching (mild, 32.2%) Bleeding (mild, 19.2%) Inflammation (moderate, 30.4%) Pain (moderate, 20.4%) Itching (moderate, 16%) Bleeding (moderate, 3%) Inflammation (severe, 9.3%) Pain (severe, 11.5%) Itching (severe, 7.8%) Bleeding (severe, 0.7%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Bleeding | 29.6% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult |
Inflammation | 49.4% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult |
Pain | 54.3% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult |
Itching | 59.3% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult |
Bleeding | 45.8% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult |
Inflammation | 79.2% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult |
Pain | 79.2% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult |
Itching | 83.3% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult |
Bleeding | 32.6% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult |
Inflammation | 52.3% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult |
Pain | 55.8% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult |
Itching | 60.5% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult |
Bleeding | 28.6% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult |
Pain | 49.6% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult |
Itching | 52.9% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult |
Inflammation | 83.2% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult |
Itching | 57.1% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult |
Inflammation | 71.4% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult |
Pain | 71.4% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult |
Bleeding | 26.8% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult |
Pain | 50.4% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult |
Itching | 52.8% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult |
Inflammation | 81.9% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult |
Bleeding | mild, 19.2% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Pain | mild, 23.7% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Inflammation | mild, 32.2% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Itching | mild, 32.2% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Itching | moderate, 16% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Pain | moderate, 20.4% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Bleeding | moderate, 3% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Inflammation | moderate, 30.4% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Bleeding | severe, 0.7% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Pain | severe, 11.5% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Itching | severe, 7.8% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Inflammation | severe, 9.3% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. | 2000 Aug 1 |
|
Imiquimod for the treatment of genital warts: a quantitative systematic review. | 2001 |
|
Consolidation therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of cytosine arabinoside, epipodophyllotoxins and cyclophosphamide. | 2001 Dec |
|
A fast and simple GC MS method for lignan profiling in Anthriscus sylvestris and biosynthetically related Plant species. | 2001 Dec |
|
Podophyllin office therapy against condyloma should be abandoned. | 2001 Dec |
|
The treatment of anogenital warts at home. | 2001 Feb 8-14 |
|
GATA-4 and serum response factor regulate transcription of the muscle-specific carnitine palmitoyltransferase I beta in rat heart. | 2001 Jan 12 |
|
A novel topoisomerase II poison GL331 preferentially induces DNA cleavage at (C/G)T sites and can cause telomere DNA damage. | 2001 Jun |
|
Management of anogenital warts (condylomata acuminata). | 2001 Nov-Dec |
|
Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation. | 2001 Oct |
|
Treatment of anogenital warts in children with topical 0.05% podofilox gel and 5% imiquimod cream. | 2001 Sep-Oct |
|
Facial molluscum: treatment with cryotherapy and podophyllotoxin. | 2002 Apr |
|
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. | 2002 Dec 15 |
|
Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. | 2002 Feb |
|
Microtubule damaging agents induce apoptosis in HL 60 cells and G2/M cell cycle arrest in HT 29 cells. | 2002 Jun 14 |
|
Deoxypodophyllotoxin; the cytotoxic and antiangiogenic component from Pulsatilla koreana. | 2002 Mar |
|
Synthesis and insecticidal activity of novel 4beta-halogenated benzoylamino podophyllotoxins against Pieris rapae Linnaeus. | 2002 Mar |
|
Constitutive expression of the Id-1 promoter in human metastatic breast cancer cells is linked with the loss of NF-1/Rb/HDAC-1 transcription repressor complex. | 2002 Mar 14 |
|
External genital warts: diagnosis, treatment, and prevention. | 2002 Oct 15 |
|
Cytogenetic analysis of giant oocytes and zygotes to assess their relevance for the development of digynic triploidy. | 2002 Sep |
|
Transcription factor IID recruitment and Sp1 activation. Dual function of TAF1 in cyclin D1 transcription. | 2003 Apr 11 |
|
Naphthalene analogues of lignans. | 2003 Feb 7 |
|
[Bacteremia due to Capnocytophaga spp.: two cases]. | 2003 Mar |
Sample Use Guides
Apply twice daily morning and evening (every 12 hours), for 3 consecutive days, then withhold use for 4 consecutive days. This 1 week cycle of treatment may be repeated up to four times until there is no visible wart tissue. Podofilox 0.5% solution is applied to the warts with a cotton-tipped applicator supplied with the drug. The drug-dampened applicator should be touched to the wart to be treated, applying the minimum amount of solution necessary to cover the lesion. Treatment should be limited to less than 10 cm2 of wart tissue and to no more than 0.5 mL of the solution per day.
Route of Administration:
Vaginal
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000008732
Created by
admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
|
||
|
NCI_THESAURUS |
C67421
Created by
admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
|
||
|
WHO-ATC |
D06BB04
Created by
admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
|
||
|
WHO-VATC |
QD06BB04
Created by
admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
10607
Created by
admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
|
PRIMARY | |||
|
7238
Created by
admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
|
PRIMARY | |||
|
SUB14925MIG
Created by
admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
|
PRIMARY | |||
|
8463
Created by
admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
|
PRIMARY | RxNorm | ||
|
m8933
Created by
admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
|
PRIMARY | Merck Index | ||
|
CHEMBL61
Created by
admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
|
PRIMARY | |||
|
24818
Created by
admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
|
PRIMARY | |||
|
518-28-5
Created by
admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
|
PRIMARY | |||
|
L36H50F353
Created by
admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
|
PRIMARY | |||
|
C29368
Created by
admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
|
PRIMARY | |||
|
PODOPHYLLOTOXIN
Created by
admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
|
PRIMARY | |||
|
3481
Created by
admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
|
PRIMARY | |||
|
100000091097
Created by
admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
|
PRIMARY | |||
|
50305
Created by
admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
|
PRIMARY | |||
|
D011034
Created by
admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
|
PRIMARY | |||
|
AA-10
Created by
admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
|
PRIMARY | |||
|
208-250-4
Created by
admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
|
PRIMARY | |||
|
DTXSID3045645
Created by
admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
|
PRIMARY | |||
|
DB01179
Created by
admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
|
PRIMARY | |||
|
L36H50F353
Created by
admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
PARENT (METABOLITE ACTIVE)